About The Study: Approximately 1 in 30 trials and more than 74,000 trial participants were affected by grant funding disruptions. Affected trials disproportionately studied infectious diseases, prevention, and behavioral interventions, and were based in the Northeastern U.S. or in other countries. Because trials require sustained financial support to ensure operations and participant safety, unanticipated funding disruptions raise concerns about avoidable waste, data quality, and compromised ethical obligations to participants.
Corresponding Author: To contact the corresponding author, Anupam B. Jena, MD, PhD, email jena@hcp.med.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.6088)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.6088?guestAccessKey=592ff841-f9a4-498e-987d-6b8c5eab0bef&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111725
Journal
JAMA Internal Medicine